(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

Patent metadata

Field	Value
Publication number	US-10668071-B2
Application number	US-201816101250-A
Country	US
Kind code	B2
Filing date	Aug 10, 2018
Priority date	Nov 5, 2013
Publication date	Jun 2, 2020
Grant date	Jun 2, 2020

Abstract

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

First claim

The invention claimed is:

1. A method of prophylaxis of bleeding in a human or animal having a disease associated with bleeding, or at risk of bleeding during or after a medical intervention, the method comprising administering an effective amount of a compound of a formula (I-A)

in which
R 1 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl;
X 1 is selected from the group consisting of nitrogen and C—R 2 ;
X 2 is selected from the group consisting of nitrogen and C—R 3 ;
X 3 is selected from the group consisting of nitrogen and C—R 4 ;
X 4 is selected from the group consisting of nitrogen and C—R 5 ;
with a proviso that 0, 1 or 2 of X 1 to X 4 are nitrogen; and
R 2 , R 3 , R 4 , and R 5 are independently from each other selected from the group consisting of hydrogen,
halogen, C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, cyano, amino, nitro, mono- or dialkylamino, hydroxy, thiol, carboxyl, C 3 -C 7 cycloalkyl, and 5 to 6 membered heteroaryl, the 5 to 6 membered heteroaryl being optionally substituted with one, two, or three substituents selected from the group consisting of C 1 -C 4 alkyl and phenyl, the phenyl being optionally substituted with one, two, or three substituents selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, and C 1 -C 4 haloalkoxy, or a group of a formula selected from the group consisting of —CO—NR 7 R 8 , —NH—CO—R 9 , —CO—O—R 9 , —CO—R 9 , —SO 2 R 10 , —SO 2 NR 11 R 12 , —SR 10 , CH 2 CN, —CH 2 NR 11 R 12 , and —CH 2 OR 10 , wherein

R 7 and R 8 independently from each other represent hydrogen, C 1 -C 4 alkyl, C 6 aryl, or 5-6 membered heteroaryl;
R 9 represents C 1 -C 4 alkyl, C 6 aryl, or 5-6 membered heteroaryl;
R 10 represents C 1 -C 4 alkyl;
R 11 and R 12 independently from each other represent hydrogen or C 1 -C 4 alkyl;

with a proviso that zero, one, two, or three of R 2 to R 5 are different from hydrogen, or a salt thereof.

2. The method of claim 1 , wherein in the compound of the formula (I-A):
R 1 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl;
X 1 is selected from the group consisting of nitrogen and C—R 2 ;
X 2 is selected from the group consisting of nitrogen and C—R 3 ;
X 3 is selected from the group consisting of nitrogen and C—R 4 ;
X 4 is selected from the group consisting of nitrogen and C—R 5 ;
with a proviso that 0, 1 or 2 of X 1 to X 4 are nitrogen; and
R 2 , R 3 , R 4 , and R 5 are independently from each other selected from the group consisting of hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, cyano, amino, nitro, mono- or dialkylamino, hydroxy, carboxyl, C 3 -C 7 cycloalkyl, and 5 to 6 membered heteroaryl, the 5 to 6 membered heteroaryl being optionally substituted with one, two, or three substituents selected from the group consisting of C 1 -C 4 alkyl and phenyl, the phenyl being optionally substituted with one, two, or three substituents selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, and C 1 -C 4 haloalkoxy;
with a proviso that zero, one, two, or three of R 2 to R 5 are different from hydrogen, or a salt thereof.

3. The method of claim 1 , wherein in the compound of the formula (I-A):
R 1 is selected from the group consisting of hydrogen and methyl;
X 1 is C—R 2
X 2 is C—R 3
X 3 is C—R 4
X 4 is C—R 5 ; and
R 2 , R 3 , and R 4 are independently from each other selected from the group consisting of hydrogen and fluorine; R 5 is selected from the group consisting of hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, cyano, amino, nitro, dialkylamino, hydroxy, carboxyl, C 3 -C 7 cycloalkyl, triazolyl (bonded via N), thiazolyl, thienyl, pyridyl, imidazolyl, pyrrolyl, and pyrazolyl (bonded via N or C), the pyrazolyl being optionally substituted with one or two substituents selected from the group consisting of C 1 -C 4 alkyl and phenyl, the phenyl being optionally substituted with one or two substituents selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, and C 1 -C 4 haloalkoxy;
with a proviso that zero, one, or two of R 2 to R 5 are different from hydrogen,
or a salt thereof.

4. The method of claim 1 , wherein in the compound of the formula (I-A):
R 1 is hydrogen;
X 1 is C—R 2
X 2 is C—R 3
X 3 is C—R 4
X 4 is C—R 5
R 2 to R 4 are hydrogen, and
R 5 is chlorine;
or a salt thereof thereof.

5. The method of claim 1 , wherein the bleeding disease or medical intervention is selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, otolaryngological surgery, dental surgery, urinary surgery, prostatic surgery, gynaecological surgery, cardiovascular surgery, and spinal surgery.

6. The method of claim 5 , wherein the medical intervention is selected from the group consisting of liver or lung transplantation, gynaecological surgery, cardiovascular surgery, and spinal surgery.

7. The method of claim 1 , wherein the bleeding disease is selected from the group consisting of stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

8. A method of prophylaxis of bleeding in a human or animal having a disease associated with bleeding, or at risk of bleeding during or after a medical intervention, the method comprising administering an effective amount of a compound of a formula (I-B)

in which
R 1 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl;
X 1 is selected from the group consisting of nitrogen and C—R 2 ;
X 2 is selected from the group consisting of nitrogen and C—R 3 ;
X 3 is selected from the group consisting of nitrogen and C—R 4 ;
X 4 is selected from the group consisting of nitrogen and C—R 5 ;
with a proviso that 0, 1 or 2 of X 1 to X 4 are nitrogen; and
R 2 , R 3 , R 4 , and R 5 are independently from each other selected from the group consisting of hydrogen,
halogen, C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, cyano, amino, nitro, mono- or dialkylamino, hydroxy, thiol, carboxyl, C 3 -C 7 cycloalkyl, and 5 to 6 membered heteroaryl, the 5 to 6 membered heteroaryl being optionally substituted with one, two, or three substituents selected from the group consisting of C 1 -C 4 alkyl and phenyl, the phenyl being optionally substituted with one, two, or three substituents selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, and C 1 -C 4 haloalkoxy, or
a group of a formula selected from the group consisting of —CO—NR 7 R 8 , —NH—CO—R 9 , —CO—O—R 9 , —SO 2 R 10 , —SO 2 NR 11 R 12 , —SR 10 , CH 2 CN, —CH 2 NR 11 R 12 , and —CH 2 OR 10 , wherein
R 7 and R 8 independently from each other represent hydrogen, C 1 -C 4 alkyl, C 6 aryl, or 5-6 membered heteroaryl;
R 9 represents C 1 -C 4 alkyl, C 6 aryl, or 5-6 membered heteroaryl;
R 10 represents C 1 -C 4 alkyl;
R 11 and R 12 independently from each other represent hydrogen or C 1 -C 4 alkyl;

with a proviso that zero, one, two, or three of R 2 to R

Assignees

• Bayer Pharma AG

Inventors

• Hassfeld Jorma
• Kinzel Tom
• Köbberling Johannes
• Cancho-Grande Yolanda
• Beyer Kristin
• Röhrig Susanne
• Köllnberger Maria
• Sperzel Michael
• Burkhardt Nils
• Schlemmer Karl-Heinz
• Stegmann Christian
• Schuhmacher Joachim
• Werner Matthias
• Ellermann Manuel

Classifications

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• C07D487/12

  in which the condensed system contains three hetero rings · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title

• C07D471/14

  Ortho-condensed systems · CPC title